Insulin receptor substrate‐4 signaling in quiescent rat hepatocytes and in regenerating rat liver

Oscar Escribano, María Dolores Fernández‐Moreno, José Antonio Zueco, Cesar Menor, Jesus Fueyo, Rosa María Ropero, Inés Diaz‐Laviada, Irene D. Román, Luis G. Guijarro – 30 December 2003 – This study was designed to characterize insulin receptor substrate‐4 (IRS‐4) in isolated rat hepatocytes and to examine its role in liver regeneration. Subcellular fractionation revealed that 85% of IRS‐4 is located at isolated hepatocyte plasma membranes. The distribution of IRS‐4 among intracellular compartments remained unchanged in insulin‐stimulated cells.

All liver recipients benefit from the protocol 10‐year liver biopsies

Mylène Sebagh, Kinan Rifai, Cyrille Féray, Funda Yilmaz, Bruno Falissard, Bruno Roche, Henri Bismuth, Didier Samuel, Michel Reynès – 30 December 2003 – The value of late protocol biopsies after liver transplantation remains to be evaluated to highlight the therapeutic policies. The study population was composed of patients who survived with the initial graft and with an available 10‐year protocol biopsy (n = 143).

Troglitazone induces p27Kip1‐associated cell‐cycle arrest through down‐regulating Skp2 in human hepatoma cells

Hironori Koga, Masaru Harada, Motoaki Ohtsubo, Shoichiro Shishido, Hiroto Kumemura, Shinichiro Hanada, Eitaro Taniguchi, Katsumi Yamashita, Ryukichi Kumashiro, Takato Ueno, Michio Sata – 30 December 2003 – Increasing evidence has confirmed that ligands for peroxisome proliferator‐activated receptor γ (PPARγ) exhibit antitumoral effects through inhibition of cell proliferation and induction of cell differentiation in several malignant neoplasms.

Recombinant human interleukin‐11 improves thrombocytopenia in patients with cirrhosis

Reem Ghalib, Cheryl Levine, Manal Hassan, Tricia McClelland, John Goss, Risë Stribling, Philip Seu, Yehuda Z. Patt – 30 December 2003 – To elucidate the hematopoietic activity of recombinant human interleukin‐11 (rhIL‐11, [Neumega, Cambridge, MA]) in patients with cirrhosis and thrombocytopenia, we administered rhIL‐11 at 50 μg/kg/d subcutaneously to 10 patients for 10 days with a 30‐day follow‐up period.

Racial differences in the relationship between hepatitis C infection and iron stores

George N. Ioannou, Jason A. Dominitz, Noel S. Weiss, Patrick J. Heagerty, Kris V. Kowdley – 30 December 2003 – Black race and increased hepatic iron stores predict poor response to interferon treatment for chronic hepatitis C virus (HCV) infection. We tested the hypothesis that these 2 observations are linked by investigating whether HCV‐infected African‐Americans have increased iron stores relative to uninfected persons.

Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug‐induced hepatitis

Yi‐Shin Huang, Herng‐Der Chern, Wei‐Juin Su, Jaw‐Ching Wu, Shi‐Chuan Chang, Chi‐Huei Chiang, Full‐Young Chang, Shou‐Dong Lee – 30 December 2003 – Most cases with antituberculosis drug‐induced hepatitis have been attributed to isoniazid. Isoniazid is metabolized by hepatic N‐acetyltransferase (NAT) and cytochrome P450 2E1 (CYP2E1) to form hepatotoxins. However, the role of CYP2E1 in this hepatotoxicity has not yet been reported. The aim of this study was to evaluate whether the polymorphism of the CYP2E1 gene is associated with antituberculosis drug‐induced hepatitis.

Subscribe to